CRISPR

Improved chemistry may make RNA editing therapies more feasible in humans.

Discover a novel approach to vaccine discovery using CRISPR engineering.

Engineered particles improve the efficiency of base editor delivery.

Researchers are using CRISPR gene editing to restore function of the mutant protein that causes Duchenne muscular dystrophy, a genetic disease that causes muscle degeneration.

An engineer turned biology researcher co-founded a bio-pharma start-up with the goal of using CRISPR to reverse the mutation causing the degenerative muscle disorder Duchenne muscular dystrophy.

LIVE October 25th, 2021 at 1:00 PM ET
Delivering CRISPR cargo in vivo to treat disease-causing DNA mutations

CRISPR gene editing directly and indirectly drives advances in cardiovascular disease therapeutic development.

A GLP-grade non-replicative Leishmania major parasite protects hamsters from lethal leishmaniasis infection, setting the stage for human clinical trials and the first potential vaccine for leishmaniasis.

Researchers employ CRISPR technology in a variety of creative ways to control the spread of vector-borne illnesses.

LIVE July 28th, 2021 at 2:30 PM ET
In this webinar, experts will discuss cytosine and adenosine base-editors to introduce point mutations in DNA strands without creating a breakpoint, and opportunities and considerations for using them.